Citations

Showing 10 of 108083 citations.

Diagnostic criteria for persistent postural-perceptual dizziness (PPPD): Consensus document of the committee for the Classification of Vestibular Disorders of the Bárány Society
Staab, Jeffrey P. , Eckhardt‐Henn, Annegret, Jacob, Rolf G. , Brandt, Thomas, Bronstein, Adolfo M. , Horii, Arata , Strupp, Michael Leo , Staab, Jeffrey P

Mayo Clinic

Journal of Vestibular Research | October 10, 2017 | Volume: 27 | Issue: 4 | Pages: 191-208

10.3233/ves-170622 | PMID 29036855 Get It

Behavioral and transcriptomic analysis of Trem2-null mice: not all knockout mice are created equal
Kang, Silvia S. , Kurti, Aishe, Baker, Kelsey E., Liu, Chia‐Chen , Ulrich, Jason D. , Bu, Guojun , Fryer, John Denis , Fryer, John D., Liu, Chia-Chen , Bu, Guojun , Colonna, Marco , Holtzman, David M.

Mayo Clinic

Human Molecular Genetics | October 10, 2017 | Volume: 27 | Issue: 2 | Pages: 211-223

10.1093/hmg/ddx366 | PMID 29040522 Get It

Age, vascular health, and Alzheimer disease biomarkers in an elderly sample
Vemuri, Prashanthi , Lesnick, Timothy G. , Przybelski, Scott A. , Lowe, Val J. , Graff‐Radford, Jonathan , Roberts, Rosebud O., Mielke, Michelle M. , Petersen, Ronald C. , Jack, Clifford R. , Jack, Clifford R , Mielke, Michelle M , Vemuri, Prashanthi , Knopman, David S. , Machulda, Mary M.

Mayo Clinic

Annals of Neurology | October 10, 2017 | Volume: 82 | Issue: 5 | Pages: 706-718

10.1002/ana.25071 | PMID 29023983 Get It

Objective To investigate the associations between age, vascular health, and Alzheimer disease (AD) imaging biomarkers in an elderly sample. Methods We identified 430 individuals along the cognitive continuum aged >60 years with amyloid positron emission tomography (PET), tau PET, and magnetic resonance imaging (MRI) scans from the population‐based Mayo Clinic Study of Aging. A subset of 329 individuals had fluorodeoxyglucose (FDG) PET. We ascertained presently existing cardiovascular and metabolic conditions (CMC) from health care records and used the summation of presence/absence of hypertension, hyperlipidemia, cardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, and stroke as a surrogate for vascular health. We used global amyloid from Pittsburgh compound B PET, entorhinal cortex tau uptake (ERC‐tau) from tau‐PET, and neurodegeneration in AD signature regions from MRI and FDG‐PET as surrogates for AD pathophysiology. We dichotomized participants into CMC = 0 (CMC − ) versus CMC > 0 (CMC + ) and tested for age‐adjusted group differences in AD biomarkers. Using structural equation models (SEMs), we assessed the impact of vascular health on AD biomarker cascade (amyloid leads to tau leads to neurodegeneration) after considering the direct and indirect age, sex, and apolipoprotein E effects. Results CMC + participants had significantly greater neurodegeneration than CMC − participants but did not differ by amyloid or ERC‐tau. The SEMs showed that (1) vascular health had a significant direct and indirect impact on neurodegeneration but not on amyloid; and (2) vascular health, specifically the presence of hyperlipidemia, had a significant direct impact on ERC‐tau. Interpretation Vascular health had quantifiably greater impact on neurodegeneration in AD regions than on amyloid deposition. Longitudinal studies are warranted to clarify the relationship between tau deposition and vascular health. Ann Neurol 2017;82:706–718
Statins and Inflammation in Cardiovascular Disease
Vogiatzi, Georgia , Oikonomou, Evangelos , Siasos, Gerasimos , Tsalamandris, Sotiris, Briasoulis, Αlexandros , Androulakis, Emmanuel , Latsios, George , Papaioannou, Spyridon , Tsioufis, Konstantinos , Tousoulis, Dimitris , Briasoulis, Alexandros , Tsalamandris, Sotirios

Mayo Clinic

Current Pharmaceutical Design | October 10, 2017 | Volume: 23 | Issue: 46 | Pages: 7027-7039

10.2174/1381612823666171009141201 | PMID 28990524 Get It

Background: Chronic inflammation and immune system activation underlie a variety of seemingly unrelated cardiac conditions including not only atherosclerosis and the subsequent coronary artery disease but also peripheral artery disease, hypertension with target organ damage and heart failure. The beneficial effects of HMG-CoA reductase inhibitors or statins are mainly attributed to their ability to inhibit hepatic cholesterol biosynthesis. Beyond their lipid lowering activity, ample evidence exists in support of their potent anti-inflammatory properties which initiate from the inhibition of GTPase isoprenylation, activating a cataract of secondary pathways and extend to the inhibition and blocking of immune cell activation and interaction. </P><P> Objective: To summarize the anti-inflammatory mechanisms of statins in clinical and experimental settings in cardiovascular disease. </P><P> Methods: A systematic search of PubMed and the Cochrane Database was conducted in order to identify the majority of trials, studies, current guidelines and novel articles related to the subject. </P><P> Results: In vitro, statins have immuno-modulatory and anti-inflammatory effects, and they can exert antiatherosclerotic effects independently of their hypolipidemic actions. In addition, positive results have emerged from mechanistic and experimental studies on the active role of HMG-CoA reductase inhibitors in HF. By extrapolating those data in clinical setting, we further understand how HMG-CoA reductase inhibitors can beneficially affect not only systolic but also diastolic HF. </P><P> Conclusion: In this review article, we present the basic pathophysiologic data supporting the anti-inflammatory actions of statins in clinical and experimental settings and we link these mechanisms with confirmatory clinical data on the potent non lipid lowering effects of HMG-CoA reductase inhibitors.
Incidence of congenital diaphragmatic hernia in Olmsted County, Minnesota: a population-based study
Woodbury, Jason M. , Bojanić, Katarina , Grizelj, Ruža , Cavalcante, Alexandre N. , Donempudi, Vinay K., Schroeder, Darrell R. , Schroeder, Darrell , Weingarten, Toby N. , Šprung, Juraj

Mayo Clinic

The Journal of Maternal-Fetal & Neonatal Medicine | October 10, 2017 | Volume: 32 | Issue: 5 | Pages: 742-748

10.1080/14767058.2017.1390739 | PMID 28992719 Get It

Sleeping Beauty Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors
Tschida, Barbara R. , Temiz, Nuri A. , Kuka, Timothy P. , Lee, Lindsey A. , Riordan, Jesse D. , Tierrablanca, Carlos A., Hullsiek, Robert, Wagner, Sandra , Hudson, Wendy A. , Amin, Khalid , Beckmann, Pauline J. , Heuer, Rachel A. , Sarver, Aaron L. , Yang, Ju Dong , Roberts, Lewis R. , Nadeau, Joseph H. , Dupuy, Adam J. , Keng, Vincent W. , Largaespada, David A. , Roberts, Lewis R , Tschida, Barbara R , Linden, Michael A. , Yang, Ju Dong , Largaespada, David A. , Temiz, Nuri A

Mayo Clinic

Cancer Research | October 9, 2017 | Volume: 77 | Issue: 23 | Pages: 6576-6588

10.1158/0008-5472.can-17-2281 | PMID 28993411 Get It

Abstract Hepatic steatosis is a strong risk factor for the development of hepatocellular carcinoma (HCC), yet little is known about the molecular pathology associated with this factor. In this study, we performed a forward genetic screen using Sleeping Beauty (SB) transposon insertional mutagenesis in mice treated to induce hepatic steatosis and compared the results to human HCC data. In humans, we determined that steatosis increased the proportion of female HCC patients, a pattern also reflected in mice. Our genetic screen identified 203 candidate steatosis-associated HCC genes, many of which are altered in human HCC and are members of established HCC-driving signaling pathways. The protein kinase A/cyclic AMP signaling pathway was altered frequently in mouse and human steatosis-associated HCC. We found that activated PKA expression drove steatosis-specific liver tumorigenesis in a mouse model. Another candidate HCC driver, the N-acetyltransferase NAT10, which we found to be overexpressed in human steatosis–associated HCC and associated with decreased survival in human HCC, also drove liver tumorigenesis in a steatotic mouse model. This study identifies genes and pathways promoting HCC that may represent novel targets for prevention and treatment in the context of hepatic steatosis, an area of rapidly growing clinical significance. Cancer Res; 77(23); 6576–88. ©2017 AACR.
IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer
Lamichhane, Purushottam , Karyampudi, Lavakumar, Shreeder, Barath , Krempski, James , Bahr, Deborah, Daum, Joshua , Kalli, Kimberly R., Goode, Ellen L. , Block, Matthew S. , Cannon, Martin J. , Knutson, Keith L. , Krempski, James W , Knutson, Keith L.

Mayo Clinic

Cancer Research | October 9, 2017 | Volume: 77 | Issue: 23 | Pages: 6667-6678

10.1158/0008-5472.can-17-0740 | PMID 28993412 Get It

Abstract Ligation of programmed cell death-1 (PD-1) in the tumor microenvironment is known to inhibit effective adaptive antitumor immunity. Blockade of PD-1 in humans has resulted in impressive, durable regression responses in select tumor types. However, durable responses have been elusive in ovarian cancer patients. PD-1 was recently shown to be expressed on and thereby impair the functions of tumor-infiltrating murine and human myeloid dendritic cells (TIDC) in ovarian cancer. In the present work, we characterize the regulation of PD-1 expression and the effects of PD-1 blockade on TIDC. Treatment of TIDC and bone marrow–derived dendritic cells (DC) with IL10 led to increased PD-1 expression. Both groups of DCs also responded to PD-1 blockade by increasing production of IL10. Similarly, treatment of ovarian tumor–bearing mice with PD-1 blocking antibody resulted in an increase in IL10 levels in both serum and ascites. While PD-1 blockade or IL10 neutralization as monotherapies were inefficient, combination of these two led to improved survival and delayed tumor growth; this was accompanied by augmented antitumor T- and B-cell responses and decreased infiltration of immunosuppressive MDSC. Taken together, our findings implicate compensatory release of IL10 as one of the adaptive resistance mechanisms that undermine the efficacy of anti–PD-1 (or anti–PD-L1) monotherapies and prompt further studies aimed at identifying such resistance mechanisms. Cancer Res; 77(23); 6667–78. ©2017 AACR.
Nanowire Aptasensors for Electrochemical Detection of Cell-Secreted Cytokines
Liu, Ying , Rahimian, Ali , Vu, Tam , Crulhas, Bruno P. , Imanbekova, Meruyert , Revzin, Alexander , Revzin, Alexander , Krylyuk, Sergiy G. , Stybayeva, Gulnaz , Shin, Dong‐Sik , Davydov, Albert V.

Mayo Clinic

ACS Sensors | October 9, 2017 | Volume: 2 | Issue: 11 | Pages: 1644-1652

10.1021/acssensors.7b00486 | PMID 28991491 Get It

What Does PLIER Really Do?
Therneau, Terry M. , Ballman, Karla V.

Mayo Clinic

Cancer Informatics | October 9, 2017 | Volume: 6 | Issue: No issue available | Pages: 117693510800600

10.1177/117693510800600008 Get It

Motivation Our goal was to understand why the PLIER algorithm performs so well given its derivation is based on a biologically implausible assumption. Results In spite of a non-intuitive assumption regarding the PM and MM errors made as part of the derivation for PLIER, the resulting probe level error function does capture the key characteristics of the ideal error function, assuming MM probes only measure non-specific binding and no signal.
Hospital outcomes of transcatheter versus surgical aortic valve replacement in female in the United States
Ando, Tomo , Akintoye, Emmanuel , Telila, Tesfaye , Briasoulis, Αlexandros , Takagi, Hisato , Schreiber, Theodore , Afonso, Luis , Briasoulis, Alexandros, Briasoulis, Alexandros , Grines, Cindy L.

Mayo Clinic

Catheterization and Cardiovascular Interventions | October 9, 2017 | Volume: 91 | Issue: 4 | Pages: 813-819

10.1002/ccd.27362 | PMID 28990736 Get It

AbstractObjectivesTo assess the in‐hospital mortality and complications in female between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR).BackgroundFemale is one of the risk factors for increased adverse events in cardiac surgery.Methods and resultsNationwide Inpatient Sample database was queried from 2011 to 2014 for patients who underwent TAVR or SAVR in female patients. The primary endpoint was in‐hospital all‐cause mortality and second endpoints were perioperative complications. We performed a propensity score analysis to calculate the adjusted odds ratio (OR) for each outcome. Patients who had concomitant cardiac surgery and those who had TAVR or SAVR mainly for aortic regurgitation were excluded. Our query from 2011 to 2014 resulted in a total of 3,067 TAVR and 18,594 SAVR in female patients. TAVR patients were in general elder and had a higher burden of comorbidities. The primary endpoint was similar between TAVR and SAVR (4.2% vs. 3.9%, OR 1.0, P = 0.89). Compared to SAVR, female TAVR patients had less hemorrhage requiring transfusion (12% vs. 21%, OR 0.41, P < 0.001), perioperative cardiac arrest and nonfatal myocardial infarction (9.8% vs. 17%, OR 0.38, P < 0.001), respiratory complication (1.6% vs. 4.4%, OR 0.28, P < 0.001), post‐op sepsis (1.7% vs. 2.9%, OR 0.65, P = 0.03), acute myocardial infarction (3.0% vs. 4.9%, OR 0.60, P < 0.001), and acute kidney injury (15% vs. 18%, OR 0.62, P < 0.001). Conversely, female TAVR patients had significantly increased risk of new pacemaker implantation (11% vs. 5.9%, OR 1.7, P < 0.001) and use of extracorporeal membrane oxygenation (0.66% vs. 0.24%, OR 2.8, P < 0.001). TAVR patients had less nonroutine discharge. The median hospital cost was significantly higher in TAVR than SAVR (median $51,274 vs. $43,677, P < 0.001) but the length of stay was shorter (mean 7.8 days vs. 10.5 days).ConclusionsTAVR may be a better option for those patients with underlying comorbidities that predispose them at higher risk for complications that was less observed in TAVR group. However, higher cost and increased risk of need for extracorporeal membrane oxygenation, although rare, should be taken into consideration upon deciding the optimal mode for aortic valve replacement.